Since stepping into her role as Chief Executive Officer of Xerimis Inc. in 2014, Carol Sue Bernardo has ushered in a period of unprecedented geographic expansion, sales growth, and capability improvements – all marked by Xerimis’ trademark emphasis on client relationships and customized quality service of the highest order.

As CEO, Carol Sue oversees the execution of all services, ranging from proposal development through distribution and accountability of clinical trial materials. Under her leadership, Xerimis Ltd. incorporated in the United Kingdom in January of 2015, ultimately building-out a robust facility and staff, licensed to meet European regulatory requirements. Simultaneously, Xerimis’ North American growth continued on an upward trajectory with positive annual sales growth.

Carol Sue joined Xerimis in 2004 as Senior Director of Operations, moving on to Vice President of Operations and then Executive Vice President in 2012. She holds degrees from the University of Southern California, the Pennsylvania State University, and Denison University. Carol Sue attributes her early professional experience in Program Development and Administration along with her work in private practice in the Health Sciences as underpinnings to a comprehensive understanding of leadership and small business practices.

Carol Sue is firmly committed to Xerimis’ legacy of superior customer service delivered with the highest level of quality and absolute dependability. She values the opportunity to work with Pharmaceutical and Biotechnology companies developing breakthrough medicines that have the potential to significantly impact health around the world in new and innovative ways.

Carol Sue is a member of the DIA (Drug Information Association), ISPE (International Society for Pharmaceutical Engineering) and AAPS (American Association of Pharmaceutical Scientists).